|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 11/13/2025
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Molecules Targeting Inflammatory Signaling
Application
A group of small molecules for treating central and peripheral diseases associated with inflammation.
Key Benefits
Applicable to a wide variety of central nervous system and peripheral diseases.
Can bypass side effects of existing therapeutics targeting similar inflammatory pathways.
High target selectivity and aqueous solubility.
Capability...
Published: 11/13/2025
Contributor(s): Raymond (Ray) Dingledine, Radhika Amaradhi, Shabber Mohammed, Thota Ganesh
|
|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 7/22/2025
Contributor(s): Jack Arbiser
|
|
Drug Screening System for Cardioprotection
Application
A high throughput screening assay for developing therapies to protect from drug and alcohol-induced cardiotoxicity.
Key Benefits
A cardiovascular stem-cell-based screening assay that can identify drugs that protect the heart from toxic medications and alcohol.
Preliminary data in the laboratory show the system is clinically relevant...
Published: 11/5/2025
Contributor(s): Chunhui Xu, Antonio Rampoldi, Yuhong Du
|
|
Small Molecules for Treating Cystic Fibrosis
ApplicationSmall molecule compounds to potentiate most common type of CFTR mutation in cystic fibrosis patients.Key BenefitsPotentiates ΔF508-hCFTR mutation, addressing more than 60 percent of CF patients. Market SummaryCystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and ion channel that malfunctions in the genetic...
Published: 2/13/2025
Contributor(s): Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
|
|
Quinazolin-4(3H)-one Derivatives as NOX-2 Inhibitors: Composition of Matter, Methods of Preparation and Their Use
Application
Quinazolin-4(3H)-one derivatives as selective NOX-2 inhibitors to prevent oxidative damage.
Key Benefits
Small molecule NOX-2 specific inhibitor.
Prevents excessive reactive oxygen species (ROS) generation rather than removing them.
Selective NOX-2 inhibition offers significant advantages to development of an effective therapy against...
Published: 11/7/2025
Contributor(s): Thota Ganesh, Radhika Amaradhi, Jacek Zielonka
|
|
Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
Application
A small molecule compound to treat Malignant Glioblastoma multiforme.
Key Benefits
Dual inhibition of NQO1 and GSTP1 induces cell death in glioblastoma cells.
Inhibition of NQO1 and GSTP1 by MNPC suppresses tumor growth and elongates the life span of the animals with GBM.
Market Summary
Approximately 30% of patients diagnosed with...
Published: 11/7/2025
Contributor(s): Keqiang Ye, Kecheng Lei
|
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type of heart...
Published: 10/3/2025
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
|
Novel Piperidine-Amide Derivatives as CXCR4 Modulators
Application
A new class of CXCR4 modulators for metastasis and inflammation.
Key Benefits
Selective for only one allosteric site on CXCR4.
Lower adverse effects.
Market Summary
Activation of the CXCR4 receptor triggers multiple signaling pathways that orchestrate cell migration, hematopoiesis and cell homing, and retention in the bone...
Published: 10/15/2025
Contributor(s): Hyunsuk Shim, Yoon Hyeun Oum
|
|
Small Molecule Compound to Treat Neurological Diseases
Application
NMDAR agents for the treatment of various neurological diseases.
Key Benefits
Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs.
The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility.
The initial studies have determined...
Published: 7/30/2024
Contributor(s): Dennis Liotta, Stephen Traynelis, Hongjie Yuan, Matthew Epplin, Samantha Summer, David Menaldino, Leon Jacobs, Adam McCallum
|
